BCL2 Inhibitor
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
New research suggests venetoclax-containing regimens with intensive treatment and may improve outcomes.
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Advertisement
Because WM is considered incurable, an important treatment consideration is optimization of quality of life.
Alexandre Bazinet, MD, and colleagues conducted the single-center, dose-expansion phase I/II trial...
The European Commission has granted Marketing Authorization for the expanded use of ibrutinib.
Advertisement
The analysis results have clinical implications, as venetoclax-based regimens are the standard of care for patients.
Lisaftoclax induced responses in patients with a variety of relapsed/refractory malignancies, including NHL and CLL.
Of 23 patients, three achieved complete remission and 15 achieved complete remission with incomplete hematological recovery.
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.
The REFINE trial observed clinically meaningful splenic responses with navitoclax plus ruxolitinib.
The results did not provide any clear benefit by adding venetoclax in patients with previously untreated follicular lymphoma.
The triplet combination resulted in a composite complete remission rate of 91%.
This article reviews the proposed mechanisms of action of venetoclax in AML and the potential future of venetoclax in AML.
This phase II study enrolled 34 adult patients with intermediate- to high-risk myelofibrosis.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.